NASDAQ:IBIO iBio (IBIO) Stock Price, News & Analysis $0.71 -0.03 (-3.42%) Closing price 04:00 PM EasternExtended Trading$0.70 -0.01 (-0.81%) As of 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About iBio Stock (NASDAQ:IBIO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get iBio alerts:Sign Up Key Stats Today's Range$0.68▼$0.7750-Day Range$0.71▼$1.3352-Week Range$0.68▼$3.82Volume588,980 shsAverage Volume1.06 million shsMarket Capitalization$49.79 millionP/E RatioN/ADividend YieldN/APrice Target$6.00Consensus RatingBuy Company Overview iBio, Inc. is a biotechnology company focused on using artificial intelligence and other computational tools to discover and develop therapies. Its research has included programs targeting obesity and metabolic diseases, as well as oncology. The company’s current approach builds on its earlier work in biologics manufacturing. Historically, iBio used its plant-based FastPharming platform to produce proteins and antibodies for research and therapeutic development. iBio is based in the United States and has shifted its focus from plant-based biologics production toward AI-enabled drug discovery. Its programs are in development, and the company’s research priorities may change as its pipeline advances.AI Generated. May Contain Errors. Read More iBio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreIBIO MarketRank™: 2.413861648555 of 5 starsiBio scored higher than 48% of companies evaluated by MarketBeat, and ranked 564th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingBuy Consensus RatingiBio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialiBio has a consensus price target of $6.00, representing about 749.0% upside from its current price of $0.71.Amount of Analyst CoverageiBio has only been the subject of 2 research reports in the past 90 days.Read more about iBio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for iBio are expected to decrease in the coming year, from ($0.35) to ($0.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of iBio is -2.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of iBio is -2.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioiBio has a P/B Ratio of 0.46. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.37% of the float of iBio has been sold short.Short Interest Ratio / Days to CoveriBio has a short interest ratio ("days to cover") of 7.15.Change versus previous monthShort interest in iBio has recently increased by 8.05%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldiBio does not currently pay a dividend.Dividend GrowthiBio does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.66 News SentimentiBio has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 15 news articles for iBio this week, compared to 2 articles on an average week.Search Interest17 people have searched for IBIO on MarketBeat in the last 30 days. This is an increase of 70% compared to the previous 30 days.MarketBeat Follows4 people have added iBio to their MarketBeat watchlist in the last 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, iBio insiders have not sold or bought any company stock.Percentage Held by Insiders1.55% of the stock of iBio is held by insiders.Percentage Held by Institutions7.90% of the stock of iBio is held by institutions.Read more about iBio's insider trading history. Receive IBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iBio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IBIO Stock News HeadlinesiBio Announces Sustained IBIO-610 Weight Reduction Data and Amylin Program Updates from Preclinical Studies2 hours ago | quiverquant.comQiBio Announces New Preclinical Data Across Obesity and Cardiometabolic Portfolio at Multiple Scientific Conferences2 hours ago | globenewswire.comDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.November 16 at 1:00 AM | Weiss Ratings (Ad)Brookline Capital Markets Boosts Earnings Estimates for iBioNovember 15 at 11:15 AM | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Talphera (TLPH) and Ibio (IBIO)November 15 at 7:05 AM | theglobeandmail.comIBio, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2026November 11, 2026 | marketscreener.comMiBio Reports Q1 Fiscal Year 2027 Financial Results and Provides Corporate UpdateNovember 10, 2026 | globenewswire.comiBio (IBIO) Set to Announce Quarterly Earnings on WednesdayNovember 10, 2026 | americanbankingnews.comSee More Headlines IBIO Stock Analysis - Frequently Asked Questions How have IBIO shares performed this year? iBio's stock was trading at $1.93 on January 1st, 2026. Since then, IBIO shares have decreased by 63.4% and is now trading at $0.7067. How were iBio's earnings last quarter? iBio, Inc. (NASDAQ:IBIO) released its quarterly earnings data on Tuesday, November, 10th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.02. The business earned $1.08 million during the quarter, compared to the consensus estimate of $25 thousand. When did iBio's stock split? Shares of iBio reverse split before market open on Wednesday, November 29th 2023.The 1-20 reverse split was announced on Wednesday, November 29th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Who are iBio's major shareholders? Top institutional investors of iBio include Marshall Wace LLP (1.09%), Noesis Capital Mangement Corp (0.39%), State Street Corp (0.34%) and Landscape Capital Management L.L.C. (0.14%). Insiders that own company stock include Felipe Duran, Martin Brenner and David Arkowitz. View institutional ownership trends. How do I buy shares of iBio? Shares of IBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of iBio own? Based on aggregate information from My MarketBeat watchlists, some other companies that iBio investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Tesla (TSLA), NIO (NIO), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD) and Moderna (MRNA). Company Calendar Last Earnings11/10/2026Today11/16/202638th Annual Healthcare Conference12/01/2026Fiscal Year End6/30/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (4m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 IBIO's financial health is in the Yellow zone, according to TradeSmith. IBIO has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:IBIO Previous SymbolNYSEMKT:IBIO CIK1420720 Webibioinc.com Phone(302) 355-0650Fax302-356-1173Employees23Year FoundedN/APrice Target and Rating Average Price Target for iBio$6.00 High Price Target$7.00 Low Price Target$5.00 Potential Upside/Downside+749.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$33.04 million Net MarginsN/A Pretax Margin-3,244.19% Return on Equity-40.05% Return on Assets-35.35% Debt Debt-to-Equity RatioN/A Current Ratio9.48 Quick Ratio9.48 Sales & Book Value Annual Sales$100 thousand Price / Sales497.94 Cash FlowN/A Price / Cash FlowN/A Book Value$1.54 per share Price / Book0.46Miscellaneous Outstanding Shares70,460,000Free Float69,364,000Market Cap$49.79 million OptionableN/A Beta1.48 Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:IBIO) was last updated on 11/16/2026 by MarketBeat.com Staff. From Our PartnersA $247 tool for $7Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full ...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredFDA clears next-gen therapy with 10 to 40 times greater potencyTime-lapse footage from a recent clinical study shows Natural Killer cells attacking and eliminating cancer ce...Market Tactic | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on E...Paradigm Press | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share iBio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.